Sadeghi: 23andMe cannot develop drugs using microarray genetic data
Kian Sadeghi · Kian Sadeghi on 23andMe’s Collapse and the Rise of Nucleus Genomics. · Mar 25, 2025 · at 3:02
Kian Sadeghi, CEO of Nucleus Genomics, critiques 23andMe's core business model of monetizing consumer genetic data for pharmaceutical research.
0:00 / 0:08exact quote · 8.1s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“They really viewed data gathering as a means to make drugs, but because it's such a small sliver of your DNA, you actually can't really make drugs off of it”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Kian Sadeghi
Sadeghi: 23andMe's genetic testing is ineffective for disease risk assessment
“Toilet meat technology missing millions and millions of genetic markers. Effectively, it's not actually useful for any really disease risk assessment.”
Sadeghi: 23andMe is not HIPAA compliant
“One of the most shocking things about 23 means is it's actually not HIPAA compliant, right? It doesn't follow the gold standard clinical regulations that ensure your data is safeguarded.”
Sadeghi predicts a whole-genome consumer health behemoth within a decade
“I really do think in the next decade, You're going to see the rise of a consumer health behemoth, and that consumer health behemoth is going to have a whole genome, the entire of someone's DNA at its foundation, and it's going to impact not just someone's heal…”
Sadeghi: Nucleus Genomics Is Years Ahead in Replacing 23andMe
“You go from Blockbuster to Netflix, you go from, you know, Blackberry to the iPhone, you go from MySpace to Facebook, and now you're going from 23 and Me to Nucleus Genomics, right? The industry is wide open, Nucleus is years ahead, and we're going to seize th…”
Sadeghi: Nucleus Genomics is exploring an acquisition of 23andMe assets
“I think one thing this nucleus actively is looking into right now, considering whether it makes sense, you know, earlier, I'm sure you remember, you know, we explored the possibility of acquiring and we're looking into right now whether that would make sense t…”